References
- Senkomago V, Henley SJ, Thomas CC, et al. Human papillomavirus-attributable cancers - United States, 2012-2016. MMWR Morb Mortal Wkly Rep. 2019;68(33):724–728.
- HPV Vaccine: Access and use in the U.S. [Internet]. Kaiser Family Foundation. 2021. [cited 2021 Oct 4]. Available at: https://www.kff.org/womens-health-policy/fact-sheet/the-hpv-vaccine-access-and-use-in-the-u-s/#.
- Genital HPV Infection – Fact Sheet [Internet]. Centers for Disease Control [cited 2021 Oct 4]. Available at: https://www.cdc.gov/std/hpv/stdfact-hpv.htm.
- Fusconi M, Grasso M, Greco A, et al. Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. Acta Otorhinolaryngol Ital. 2014;34(6):375–381.
- Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008;1(1):2–10.
- Kreisel KM, Spicknall IH, Gargano JW, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. Sex Transm Dis. 2021;48(4):208–214.
- How many cancers are linked with HPV each year [Internet]? Centers for Disease Control. 2018. [cited 2021 May 17]. Available at: https://www.cdc.gov/cancer/hpv/statistics/cases.htm.
- Centers for Disease Control HPV-Associated Cancer Statistics 2020 [Internet]. Centers for Disease Control [cited 2021 May 14]. Available at https://www.cdc.gov/cancer/hpv/statistics/.
- Liao C-I, Caesar MAP, Chan C, et. al. HPV associated cancers in the United States over the last 15 years: has screening or vaccination made any difference? J Clin Oncol. 2021;39(15_suppl):107–107.
- Centers for Disease Control and Prevention: HPV and oropharyngeal cancer. U.S. Department of Health and Human Services. [cited 2021 Dec 6]. https://www.cdc.gov/cancer/hpv/basic_info/hpv_oropharyngeal.htm.
- Shay SG, Chang E, Lewis MS, et al. Characteristics of human papillomavirus–associated head and neck cancers in a veteran population. JAMA Otolaryngol Head Neck Surg. 2015;141(9):790–796.
- Agan BK, Macalino GE, Nsouli-Maktabi H, et al. Human papillomavirus seroprevalence among men entering military service and seroincidence after ten years of service. MSMR. 2013;20(2):21–24.
- Singh JA, Borowsky SJ, Nugent S, et al. Health‐related quality of life, functional impairment, and healthcare utilization by veterans: veterans' quality of life study. J Am Geriatr Soc. 2005;53(1):108–113.
- Chesson HW, Ekwueme DU, Saraiya M, et al. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30(42):6016–6019.
- Chesson HW, Meites E, Ekwueme DU, et al. Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States. Hum Vaccin Immunother. 2019;15(7–8):1942–1948.
- Van Dyne EA, Henley SJ, Saraiya M, et al. Trends in human papillomavirus–associated cancers—United States, 1999–2015. MMWR Morb Mortal Wkly Rep. 2018;67(33):918–924.
- Washington DL, Bean-Mayberry B, Riopelle D, et al. Access to care for women veterans: delayed healthcare and unmet need. J Gen Intern Med. 2011;26(S2):655–661.
- Panangala SV, Carey MP, Dortch C, et al. Veterans Access, Choice, and Accountability Act of 2014 (HR 3230; PL 113-146) [Internet]. Congressional Research Service. 2015 Aug 27 [cited 2021 Oct 11]. Available at: https://sgp.fas.org/crs/misc/R43704.pdf.
- Sayre GG, Neely EL, Simons CE, et al. Accessing care through the veterans choice program: the veteran experience. J Gen Intern Med. 2018;33(10):1714–1720.
- Høxbroe Michaelsen S, Grønhøj C, Høxbroe Michaelsen J, et al. Quality of life in survivors of oropharyngeal cancer: a systematic review and Meta-analysis of 1366 patients. Eur J Cancer. 2017;78:91–102.
- Conway EL, Farmer KC, Lynch WJ, et al. Quality of life valuations of HPV-associated cancer health states by the general population. Sex Transm Infect. 2012;88(7):517–521.
- Boersma P, Black LI. Human papillomavirus vaccination among adults aged 18-26, 2013-2018 [Internet]. Centers for Disease Control and Prevention. 2020 Jan [cited 2021 Oct 11]. Available at: https://www.cdc.gov/nchs/data/databriefs/db354-h.pdf.
- Nobel T, Rajupet S, Sigel K, et al. Using veterans affairs medical center (VAMC) data to identify missed opportunities for HPV vaccination. Hum Vacc Immunother. 2019;15(7–8):1878–1883.
- Buechel JJ. Vaccination for human papillomavirus: immunization practices in the U.S. military. Clin J Oncol Nurs. 2018;22(1):104–107.
- Clark LL, Stahlman S, Taubman SB. Human papillomavirus vaccine initiation, coverage, and completion rates among U.S. active component service members, 2007-2017. MSMR. 2018;25(9):9–14.
- Collins MK, Tarney C, Craig ER, et al. Human papillomavirus vaccination rates of military and civilian male respondents to the behavioral risk factors surveillance system between 2013 and 2015. Mil Med. 2019;184(Supplement_1):121–125.
- Lairson DR, Fu S, Chan W, et al. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas. Gynecol Oncol. 2017;145(1):108–113.
- Lairson DR, Wu CF, Chan W, et al. Medical care cost of oropharyngeal cancer among Texas patients. Cancer Epidemiol Biomarkers Prev. 2017;26(9):1443–1449.
- Fu S, Lairson DR, Chan W, et al. Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas. Gynecol Oncol. 2018;148(2):342–348.
- About VHA [Internet]. U.S. Department of Veterans’ Affairs, Veterans’ Health Administration [cited 2021 Apr 1]. Available at: https://www.va.gov/health/aboutvha.asp.
- United States Cancer Statistics: Data Visualization USCS Data Visualizations – CDC [Internet]. Centers for Disease Control [cited 2021 May 17]. https://www.cdc.gov/cancer/uscs/dataviz/index.htm.
- Mix JM, Van Dyne EA, Saraiya M, et al. Assessing impact of HPV vaccination on cervical cancer incidence in women 15–29 years in the United States, 1999–2017: an ecologic study. Cancer Epidemiol Biomarkers Prev. 2021;30(1):30–37.
- Commission on Care Final Report, June 30, 2016. [Internet]. Stars and Stripes [cited 2021 Oct 11]. Available at https://s3.amazonaws.com/sitesusa/wp-content/uploads/sites/912/2016/07/Commission-on-Care_Final-Report_063016_FOR-WEB.pdf.
- O’Hanlon C, Huang C, Sloss E, et. al. Comparing VA and non-VA quality of care: a systematic review. J Gen Intern Med. 2017;32(1):105–121.:
- Blay E, Jr., DeLancey JO, Hewitt DB, et al. Initial public reporting of quality at veterans affairs vs. non-veterans affairs hospitals. JAMA Intern Med. 2017;177(6):882–885.
- Syler LB, Stobaugh CL, Foulis PR, et al. Cervical cancer screening in South Florida veteran population, 2014 to 2020: cytology and high-risk human papillomavirus correlation and epidemiology. Cureus. 2021;13(8):e17247.
- Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus–associated cancers—United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661–666.
- Anantharaman D, Muller DC, Lagiou P, et. al. Combined effects of smoking and HPV16 in oropharyngeal cancer. Int J Epidemiol. 2016;45(3):752–761.
- Jiang X, Wu J, Wang J, et. al. Tobacco and oral squamous cell carcinoma: a review of carcinogenic pathways. Tob Induc Dis. 2019;17(April):29.
- Brown DW. Smoking prevalence among US veterans. J Gen Intern Med. 2010;25(2):147–149.
- Horsky J, Drucker EA, Ramelson HZ. Accuracy and completeness of clinical coding using ICD-10 for ambulatory visits. AMIA Annu Symp Proc. 2017;2017:912–920.
- Tanaka TI, Alawi F. Human papillomavirus and oropharyngeal cancer. Dent Clin North Am. 2018;62(1):111–120.
- Taberna M, Mena M, Pavón MA, et. al. Human papillomavirus-related oropharyngeal cancer. Ann Oncol. 2017;28(10):2386–2398.
- Lairson DR, Wu CF, Chan W, et al. Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States. Urol Oncol. 2019;37(4):294.e17–294.e25.
- Wu CF, Xu L, Fu S, et al. Health care costs of anal cancer in a commercially insured population in the United States. J Manag Care Spec Pharm. 2018;24(11):1156–1164.
- FDA News Release. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old [Internet]. US Food and Drug Administration. 2018. [cited 2021 May 17]. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old.
- Cancers Associated with Human Papillomavirus, United States—2013–2017. US Cancer Statistics Data Briefs, No 18 [Internet]. Centers for Disease Control. 2020. [cited 2021 May 12]. Available at: https://www.cdc.gov/cancer/uscs/about/data-briefs/no18-hpv-assoc-cancers-UnitedStates-2013-2017.htm.
- Kjaer SK, Nygård M, Sundström K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine. 2020;23:100401.
- Gardasil 9 [Internet]. U.S. Food & Drugs Administration. 2020. [cited 2021 Jul 7]. Available at: https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil-9.
- Army Shots - Basic Training Vaccinations List [Internet]. US Army Basic [cited 2021 May 17]. Available at: https://usarmybasic.com/about-the-army/army-shots.
- NCI-Designated Cancer Centers Endorse Goal of Eliminating HPV-Related Cancers [Internet]. National Cancer Institute and Affiliated Institutions. [cited 2021 May 12]. Available at http://hpvroundtable.org/wp-content/uploads/2018/06/Cancer-Center-HPVConsensusStatement_FINAL_06.01.2018.pdf.
- Schuttner L, Haraldsson B, Maynard C, et. al. Factors associated with low-value cancer screenings in the veterans health administration. JAMA Netw Open. 2021;4(10):e2130581.
- Rotsides JM, Oliver JR, Moses LE, et. al. Socioeconomic and racial disparities and survival of human papillomavirus-associated oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2021;164(1):131–138.